FDA approved Narcan naloxone nasal spray as prescription overdose-reversal medicine
Dated 18 November 2015: FDA approved Narcan naloxone nasal spray as prescription overdose-reversal medicine. In the causal graph this event weakens North America opioid / fentanyl crisis, a driver that strengthens Preventable mortality rate — an improving welfare path.
Who was responsible
Contribution type and responsibility level for each recorded actor — not sole-author shorthand.
No public contributors are listed for this fact.
What changed
Fact → Driver → Indicator. Relationship strength orders the paths; it is not the observed indicator movement.
- FactFDA approved Narcan naloxone nasal spray as prescription overdose-reversal medicine
- weakensDriverNorth America opioid / fentanyl crisis
- strengthensIndicators (2)Preventable mortality rate
provisional weight · verified
Strengthens · 75% impact strength (driver → indicator)
Observed
173 deaths per 100,000 population · 47.9 above the normal line (2023)
Worse than normal6 readings, 2018–2023: fell from 174 deaths per 100,000 population to 173 deaths per 100,000 population.
Above normal = worse
Weakens · 70% impact strength (driver → indicator)
Observed
80 Years · 2.3 below the normal line (2023)
Worse than normal6 readings, 2018–2023: rose from 79.5 Years to 80 Years.
Above normal = better
Causal path
How this event connects to drivers and indicators in the graph.
- FactFDA approved Narcan naloxone nasal spray as prescription overdose-reversal medicine
- weakensDriverNorth America opioid / fentanyl crisis
- strengthensIndicatorPreventable mortality rate
Cite this page
Factrail. (2026). FDA approved Narcan naloxone nasal spray as prescription overdose-reversal medicine. Factrail. https://factrail.ai/facts/fda-narcan-nasal-spray-prescription-approval-2015
https://factrail.ai/facts/fda-narcan-nasal-spray-prescription-approval-2015
Accessed 15 October 2026.
By the Factrail desk · Method: how we source and score · Last reviewed
Dispute this factNamed here, or represent someone who is? Request a right of reply.